- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01221519
A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients
January 18, 2012 updated by: AstraZeneca
Randomized, Open, 4-way Crossover, Single Center, Phase I Relative Bioavailability Study in Type 2 Diabetes Mellitus Patients to Measure the Extent and Rate of Absorption of AZD1656 From Different Tablet Formulations
The purpose of this study is to assess the relative bioavailability by measuring the extent and rate of absorption of different tablet formulations of AZD1656 in T2DM patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
St. Paul, Minnesota, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study specific procedures.
- Males or females of non-childbearing potential (post-menopausal, and/or have undergone hysterectomy and/or bilateral oophorectomy or salpingectomy/ tubal ligation) aged ≥18 years. Females will be defined as post-menopausal if last menstruation period was >1 year ago and serum follicle stimulating hormone (FSH) is within the post-menopausal range, or if age >50 years and with last menstruation period >2 years ago.
- A confirmed clinical diagnosis of T2DM for at least 1 year, treated with metformin as a single treatment or in combination with one other oral anti-diabetic (ie, DPPIV inhibitor or SU) for at least 2 months prior to screening. Doses of anti-diabetic treatment should have been stable for at least 1 month prior to screening.
- Treatment with at least 1000mg of Metformin for 2 months and being stable on the Metformin Therapy for 1 month
- Hb A1c >6.5% (international standard) at enrolment.
- Body mass index (BMI) between ≥19 and ≤42 kg/m2.
Exclusion Criteria:
- Clinically significant illness or clinically relevant trauma, as judged by the Investigator, within 2 weeks prior to the first administration of AZD1656
- Participation in another clinical study during the 30 days prior to screening or intake of another investigational drug within 30 days (or at least 5 x t1/2 of the drug) prior to the first administration of AZD1656.
- History of, or ongoing, ischemic heart disease or heart failure. Stroke, transitory ischemic attack, or symptomatic peripheral arterial disease within the last 6 months.
- Clinically significant abnormalities in ECG, clinical chemistry, hematology or urinalysis results.
- Positive test for Hepatitis B surface antigen (HBsAg) or antibodies to human immunodeficiency virus (HIV) or Hepatitis C virus.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
AZD1656
|
3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
|
Experimental: 2
AZD1656
|
3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
|
Experimental: 3
AZD1656
|
3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of AUC of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 1
|
Blood samples will be collected from predose to 48 hrs at each treatment period 1
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of Cmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 1
|
Blood samples will be collected from predose to 48 hrs at each treatment period 1
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 1
|
Blood samples will be collected from predose to 48 hrs at each treatment period 1
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of AUC of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 2
|
Blood samples will be collected from predose to 48 hrs at each treatment period 2
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of Cmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 2
|
Blood samples will be collected from predose to 48 hrs at each treatment period 2
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 2
|
Blood samples will be collected from predose to 48 hrs at each treatment period 2
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of AUC of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 3
|
Blood samples will be collected from predose to 48 hrs at each treatment period 3
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of Cmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 3
|
Blood samples will be collected from predose to 48 hrs at each treatment period 3
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 3
|
Blood samples will be collected from predose to 48 hrs at each treatment period 3
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of AUC of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 4
|
Blood samples will be collected from predose to 48 hrs at each treatment period 4
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of Cmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 4
|
Blood samples will be collected from predose to 48 hrs at each treatment period 4
|
Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.
Time Frame: Blood samples will be collected from predose to 48 hrs at each treatment period 4
|
Blood samples will be collected from predose to 48 hrs at each treatment period 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the safety of AZD1656 by assessing a panel of adverse events measures: physical examination, electrocardiogram, pulse and blood pressure, weight and laboratory, variables including plasma glucose.
Time Frame: start of treatment until follow up
|
start of treatment until follow up
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-t).
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of Cmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of tmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of t½.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 1
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-t).
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of Cmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of tmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of t½.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 2
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-t).
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of Cmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of tmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of t½.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 3
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-t).
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of Cmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of tmax.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
Evaluate: pharmacokinetics of the AZD1656 metabolite, following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of t½.
Time Frame: PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
PK blood samples will be collected from predose to 48 hrs after each treatment period 4
|
pharmacodynamics of AZD1656 following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-4) and AUC(0-24) for glucose
Time Frame: PK blood samples will be collected from predose to 48 hrs after treatment period and P-glucose on Day 1 of each treatment period
|
PK blood samples will be collected from predose to 48 hrs after treatment period and P-glucose on Day 1 of each treatment period
|
pharmacodynamics of AZD1656 following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-4) for insulin
Time Frame: PK blood samples will be collected from predose to 48 hrs after treatment period and P-glucose on Day 1 of each treatment period
|
PK blood samples will be collected from predose to 48 hrs after treatment period and P-glucose on Day 1 of each treatment period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Eva Johnsson, MD, PhD, AstraZeneca Sweden
- Study Chair: Mirjana Kujacic Kujacic, MD, PhD, AstraZeneca R&D Mölndal
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
January 1, 2011
Study Completion (Actual)
January 1, 2011
Study Registration Dates
First Submitted
October 12, 2010
First Submitted That Met QC Criteria
October 14, 2010
First Posted (Estimate)
October 15, 2010
Study Record Updates
Last Update Posted (Estimate)
January 19, 2012
Last Update Submitted That Met QC Criteria
January 18, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1020C00033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
HighTide Biopharma Pty LtdRecruitingT2DM (Type 2 Diabetes Mellitus)China
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
Clinical Trials on AZD1656
-
AstraZenecaCompleted
-
AstraZenecaCompleted
-
AstraZenecaCompleted
-
AstraZenecaCompletedType II Diabetes MellitusUnited States
-
AstraZenecaCompletedGlucose LoweringUnited States
-
AstraZenecaCompletedHealthy VolunteersUnited States
-
Queen Mary University of LondonAstraZenecaActive, not recruitingDiabetes Mellitus, Type 2 | End Stage Renal Disease | Type 2 Diabetes | Renal Transplant | Kidney Transplant; ComplicationsUnited Kingdom
-
St George Street CapitalCompletedCovid19Czechia, Romania, United Kingdom
-
AstraZenecaCompleted
-
AstraZenecaCompletedType 2 Diabetes MellitusJapan